Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 in Refractory Metastatic Renal Cell Carcinoma
NCT00303862Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cediranib in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 6 weeks. Started Mar 2006; status: terminated.
02
Drugs
cediranib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00303862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303862.